Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Phase 1 Clinical Studies Completed: NTX-253 for the Treatment of Schizophrenia
3
How a Learning Health Network Could Transform Bipolar Disorder Treatment: A Conversation With Andrew Nierenberg, MD
4
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
5